Objectif The direct annual cost of diabetes is more than €736 billion, with 15% accounting for antidiabetic drugs, 24% for other pharmaceutical compounds and 61% for primary care and hospitalisations. But the social impact is also huge, with 51% of patients experimenting emotional anxiety, 17% having depression episodes and 19% feeling discriminated because of the condition. Control of glucose in blood (combining diet, physical activity and medication if necessary), control of blood pressure and lipids, and regular screening for damage to the eyes, kidneys and feet, are cost-effective interventions in diabetes management. 1% reduction of HbA1c levels reduces heart attacks by 14%, microvascular complications by 37% and diabetes-related deaths by 21%.SocialDiabetes is a mHealth solution that can reduce HbA1c levels to normal values (6.4%) in 6 months of continuous use. It is based in a set of proprietary algorithms integrated in a mobile application and a web platform where patients can log data (glucose measurements, food intake, insulin administration, exercise) and doctors can monitor the disease. The app also calculates insulin doses, which is a unique feature compared to similar apps, and offers integration with glucose meters from major providers. Currently the solution is being exploited through a B2C model, with a free and a premium subscription plans.The aim of the project is to implement a B2B model catching the attention of major healthcare providers and stakeholders (public and private hospitals, governments, insurers) so they would adopt SocialDiabetes as the standard tool for disease management. The business opportunity lies in the benefits for the health of patients and ultimately in the reduction of costs for the whole system. Product and business development strategic plans have been designed accordingly. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineendocrinologydiabetesnatural sciencesbiological sciencesbiochemistrybiomoleculeslipidsmedical and health scienceshealth sciencesnutritionmedical and health sciencesclinical medicinecardiologycardiovascular diseases Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Thème(s) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-2-2016-2017 Régime de financement SME-2 - SME instrument phase 2 Coordinateur SOCIALDIABETES SL Contribution nette de l'UE € 1 622 001,85 Adresse AVINGUDA DIAGONAL 56 PLATA 6 PUERTA 3 08019 BARCELONA Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Este Cataluña Barcelona Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 2 317 145,50
